About Scancell
Scancell is a company based in Nottingham (United Kingdom) founded in 1997. It operates as a HealthTech. Scancell has raised $5.84 million across 12 funding rounds from investors including Calculus Capital, Oxford Technology and UK Research and Innovation. Scancell offers products and services including iSCIB1+ and Moditope Peptide Therapy. Scancell operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Nottingham, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Scancell Holdings Plc
-
Annual Revenue
$6.29 M (USD)0as on Apr 30, 2025
-
Net Profit
-$16.38 M (USD)-109.46as on Apr 30, 2025
-
EBITDA
-$18.85 M (USD)18.37as on Apr 30, 2025
-
Total Equity Funding
$5.84 M (USD)
in 12 rounds
-
Latest Funding Round
$14.41 M (USD), Post-IPO
Dec 10, 2024
-
Investors
Calculus Capital
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Scancell
Scancell is a publicly listed company on the LSE with ticker symbol SCLP in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Scancell
Scancell offers a comprehensive portfolio of products and services, including iSCIB1+ and Moditope Peptide Therapy.
An Immunobody DNA therapy for advanced melanoma treatment.
A peptide therapy targeting various solid tumor cancers.
People of Scancell
Unlock access to complete
Unlock access to complete
Funding Insights of Scancell
Scancell has successfully raised a total of $5.84M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $14.41 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Scancell
Scancell has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Calculus Capital, Oxford Technology and UK Research and Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
UK venture capital investments are managed by Calculus Capital.
|
Locked | Locked | Locked | |
|
Early-stage venture capital is invested in UK technology sectors.
|
Locked | Locked | Locked | |
|
Early-stage micro-VC investments are focused on UK companies.
|
Locked | Locked | Locked |
Investor details for Scancell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scancell
Investment portfolio details for Scancell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Scancell
Detailed financials for Scancell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scancell Comparisons
Peer comparison for Scancell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scancell
Scancell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Scancell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scancell
Complete news archive for Scancell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scancell
Scancell was founded in 1997 and raised its 1st funding round 6 years after it was founded.
Scancell is headquartered in Nottingham, United Kingdom.
Scancell is a funded company, having raised a total of $5.84M across 12 funding rounds to date.
Annual revenue of Scancell is $6.29M as on Apr 30, 2025.
Scancell is engaged in the development of active immunotherapies aimed at treating cancer by enhancing long-lasting tumor-specific immunity. The company utilizes proprietary platforms such as Immunobody and Moditope to create potent therapies for hard-to-treat cancers. Solutions like iSCIB1 target advanced melanoma with safe and effective immune responses, while Moditope therapies address a broad range of solid tumors. The focus remains on delivering patient-accessible treatments that transform cancer care standards across the healthcare sector.
Scancell's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Scancell offers iSCIB1+ and Moditope Peptide Therapy.
Yes, Scancell is publicly traded on LSE under the ticker symbol SCLP.
Scancell has 6 investors. Key investors include Calculus Capital, Oxford Technology, UK Research and Innovation, Seneca Growth Capital, and Redmile Group.
The ticker symbol of Scancell is SCLP on LSE.